# A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

> **NCT03035253** · PHASE1 · TERMINATED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** OMP-305B83
- **DRUG:** FOLFIRI
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT03035253
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2018-09
- **Final completion:** 2018-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035253, "A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03035253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*